Pop Parliament TRIPS up Pro-industry agreements, dampens emerging markets
This article was originally published in Scrip
Flushed from their success in blocking the Anti-Counterfeiting Trade Agreement (ACTA), key political groups from the European Parliament's are now turning their attention to other EU trade agreements that might threaten access to medicines in emerging markets and developing countries. Representatives of three separate European parliamentary groups have told Scrip that they would be looking out for anything in European Commission proposals on trade that might limit poorer nations' access to healthcare products, including so-called TRIPS Plus measures.
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.